González-Martín, A., Alba, E., Ciruelos, E., Cortés, J., Llombart, A., Lluch, A., Andrés, R., álvarez, I., Aramendía, J.M., de la Pena, F.A., Barnadas, A., Batista, N., Calvo, L., Galve, E., García-Palomo, A., García-Sáenz, J.á., de la Haba, J., López, R., López-Vivanco, G., Martínez-Jánez, N., de Duenas, E.M., Plazaola, A., Rodríguez-Lescure, á., Ruiz, M., Sánchez-Rovira, P., Santaballa, A., Seguí, M.á., Tusquets, I., Zamora, P. and Martín, M. (2016) Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Current Cancer Drug Targets, 16, 415-428.
https://doi.org/10.2174/1568009615666150817121731

has been cited by the following article:

• TITLE: Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient

  AUTHORS: Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia

  KEYWORDS: Nab-Paclitaxel, Trastuzumab, HER-2, Metastasis, Breast Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.11, November 16, 2017

  ABSTRACT: Background: Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However, the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade, nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation: We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.